TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36946232

Group type: COMPARATOR
Intervention: High-Dose Prophylactic Anticoagulation (HD-PA)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Therapeutic Anticoagulation (TA)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Standard-Dose Prophylactic Anticoagulation (SD-PA)
Number of subjects: 334
Study: 36946237

Group type: EXPERIMENTAL
Intervention: Tedopi
Number of subjects: 0
Study: 36946293

Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: EQ-5D index scores 0.800 or more
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: Higher EQ-5D index scores
Number of subjects: 1684
Study: 36946298

Group type: EXPERIMENTAL
Intervention: Oxycodone treatment, dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36946321

Group type: EXPERIMENTAL
Intervention: Local flaps
Number of subjects: 30

Group type: COMPARATOR
Intervention: Skin grafts
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 30
Study: 36946359

Group type: EXPERIMENTAL
Intervention: dPTFE (partially exposed non-absorbable membrane)
Number of subjects: 44

Group type: COMPARATOR
Intervention: USH (unassisted socket healing)
Number of subjects: 44
Study: 36946420

Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention focused on caloric restriction, increased physical activity, and diet
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 5145
Study: 36946440

Group type: EXPERIMENTAL
Intervention: At-home aerobic and/or resistance exercise intervention for 16 weeks
Number of subjects: 24
Study: 36946443

Group type: EXPERIMENTAL
Intervention: High-dose aducanumab (10 mg/kg) in EMERGE
Number of subjects: 3285

Group type: EXPERIMENTAL
Intervention: Low-dose aducanumab
Number of subjects: 3285

Group type: COMPARATOR
Intervention: High-dose aducanumab in ENGAGE
Number of subjects: 3285

Group type: EXPERIMENTAL
Intervention: Later enrolled patients randomized to target dosing regimen of 10 mg/kg
Number of subjects: 3285
Study: 36946448

Group type: EXPERIMENTAL
Intervention: Crenezumab (Phase 2 studies ABBY and BLAZE)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Placebo (Phase 2 studies ABBY and BLAZE)
Number of subjects: 463
Study: 36946505

Group type: EXPERIMENTAL
Intervention: Booster vaccination (BV) using inactivated virus vaccines (the third dose)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 114
Study: 36946603

Group type: EXPERIMENTAL
Intervention: 400 mg solanezumab every 4 weeks for 80 weeks
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo every 4 weeks for 80 weeks
Number of subjects: 3
Study: 36946605

Group type: EXPERIMENTAL
Intervention: Olanzapine/Samidorphan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36946749

Group type: EXPERIMENTAL
Intervention: SJW-PDT
Number of subjects: 31

Group type: COMPARATOR
Intervention: IAA-PDT
Number of subjects: 31
Study: 36947030

Group type: EXPERIMENTAL
Intervention: Augmented double wide-area circumferential ablation (WACA)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Standard single wide-area circumferential ablation (WACA)
Number of subjects: 398
Study: 36947036

Group type: EXPERIMENTAL
Intervention: Moderate-severity cluster
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: High-severity cluster
Number of subjects: 706

Group type: COMPARATOR
Intervention: Low-severity cluster
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Toxic effects
Number of subjects: 706
Study: 36947042

Group type: EXPERIMENTAL
Intervention: Topical lovastatin 2% plus cholesterol 2% cream (lovastatin-cholesterol); applied once or twice daily for 12 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Topical lovastatin 2% cream (lovastatin); applied once or twice daily for 12 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Adverse events reported in both groups
Number of subjects: 32
Study: 36947125

Group type: EXPERIMENTAL
Intervention: Intervention involving trained community health workers conducting home visits and providing support for PWUD and their families.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition (details not specified in the abstract).
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intervention involving community health workers' service provision.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intervention involving family members' support.
Number of subjects: 60
Study: 36947155

Group type: EXPERIMENTAL
Intervention: Regional anesthesia in super-obese parturients
Number of subjects: 494

Group type: COMPARATOR
Intervention: Regional anesthesia in morbidly obese parturients
Number of subjects: 494
Study: 36947201

Group type: EXPERIMENTAL
Intervention: Novel 2-stage diagnostic classifier based on mutational profiles in 18 of 53 sequenced genes
Number of subjects: 1298

Group type: EXPERIMENTAL
Intervention: Novel 2-stage diagnostic classifier based on variant allele frequencies (VAFs) in 10 genes
Number of subjects: 1298

Group type: COMPARATOR
Intervention: Classifier-predicted diagnosis
Number of subjects: 1298
Study: 36947263

Group type: EXPERIMENTAL
Intervention: VFRs fabricated on conventional models
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: VFRs fabricated on FDM models
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: VFRs fabricated on SLA models
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lower VFRs
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: SLA models
Number of subjects: 36

Group type: COMPARATOR
Intervention: Surface roughness
Number of subjects: 36
Study: 36947322

Group type: EXPERIMENTAL
Intervention: Low-sodium oxybate (LXB) during OLOTTP/SDP
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Low-sodium oxybate (LXB) during OLE
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Low-sodium oxybate (LXB) during OLOTTP/SDP and OLE
Number of subjects: 201
Study: 36947466

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 100

Group type: COMPARATOR
Intervention: No caffeine
Number of subjects: 100
Study: 36947489

Group type: EXPERIMENTAL
Intervention: micro intervention condition (immediate positive parenting feedback)
Number of subjects: 120

Group type: COMPARATOR
Intervention: care-as-usual control condition
Number of subjects: 120
Study: 36947521

Group type: EXPERIMENTAL
Intervention: ICSI/PGTA+GS (n = 105)
Number of subjects: 1317

Group type: EXPERIMENTAL
Intervention: ICSI/PGTA+GS (n = 46)
Number of subjects: 1317

Group type: COMPARATOR
Intervention: ICSI/PGTA (n = 1,212)
Number of subjects: 1317
Study: 36947589

Group type: EXPERIMENTAL
Intervention: Nordi-tropin (somatropin, Novo Nordisk) at a mean dose of 0.045 (0.011) mg/kg/day
Number of subjects: 2377

Group type: EXPERIMENTAL
Intervention: Nordi-tropin (somatropin, Novo Nordisk)
Number of subjects: 2377
Study: 36947593

Group type: EXPERIMENTAL
Intervention: ASO therapy targeting an evolutionarily conserved region at the start of the UBE3A gene
Number of subjects: 0
Study: 36947713

Group type: EXPERIMENTAL
Intervention: Metformin + Leucine (MET+LEU) treatment
Number of subjects: 0
Study: 36947734

Group type: EXPERIMENTAL
Intervention: Naporafenib 200 mg twice a day plus trametinib 1 mg once daily
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Naporafenib 400 mg twice a day plus trametinib 0.5 mg once daily
Number of subjects: 66
Study: 36947969

Group type: EXPERIMENTAL
Intervention: Increased energy intake (Oligo/Amen+Cal)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Oligo/Amen Control
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both groups (Oligo/Amen+Cal and Oligo/Amen Control)
Number of subjects: 113
Study: 36947970

Group type: EXPERIMENTAL
Intervention: Indeterminate diastolic dysfunction
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Diastolic dysfunction
Number of subjects: 218

Group type: COMPARATOR
Intervention: Normal diastolic function
Number of subjects: 218
Study: 36948246

Group type: EXPERIMENTAL
Intervention: D-1553 (garsorasib) 600 mg twice a day
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: D-1553 (garsorasib) at recommended phase 2 dose
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: D-1553 (garsorasib) in patients with brain metastasis
Number of subjects: 79
Study: 36948325

Group type: EXPERIMENTAL
Intervention: Pain-specific acupoints
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Depression-specific acupoints
Number of subjects: 47
Study: 36948372

Group type: EXPERIMENTAL
Intervention: NOV03 (perfluorohexyloctane) ophthalmic drop, 4 times daily for 8 weeks
Number of subjects: 620

Group type: COMPARATOR
Intervention: Hypotonic saline (0.6%), 4 times daily for 8 weeks
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Both NOV03 and saline
Number of subjects: 620
Study: 36948424

Group type: EXPERIMENTAL
Intervention: Screening Colonoscopy
Number of subjects: 3523

Group type: COMPARATOR
Intervention: Sequential HSgFOBT
Number of subjects: 3523

Group type: EXPERIMENTAL
Intervention: Crossover to Screening Colonoscopy
Number of subjects: 3523
Study: 36948488

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 489
Study: 36948504

Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nivolumab/ipilimumab salvage therapy
Number of subjects: 35
Study: 36948505

Group type: EXPERIMENTAL
Intervention: PrCa VBIR (adenovirus vector and plasmid DNA expressing PSMA, PSA, PSCA) plus tremelimumab 80 mg and sasanlimab 300 mg (RP2D) in mCRPC
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: PrCa VBIR plus tremelimumab 80 mg (Cohort 1B-BCR) in BCR
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: PrCa VBIR plus tremelimumab 80 mg plus sasanlimab 130 mg (Cohort 5B-BCR) in BCR
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: PrCa VBIR in mCRPC
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: PrCa VBIR overall
Number of subjects: 91
Study: 36948531

Group type: EXPERIMENTAL
Intervention: Proactive home visits by community health workers (CHWs)
Number of subjects: 5112

Group type: COMPARATOR
Intervention: Passive site-based care by community health workers (CHWs)
Number of subjects: 5112
Study: 36948547

Group type: EXPERIMENTAL
Intervention: mTBI cohort
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control cohort
Number of subjects: 148
Study: 36948565

Group type: EXPERIMENTAL
Intervention: NTDT-PRO questionnaire
Number of subjects: 145
Study: 36948567

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy components (mindful attention, decentring, values and committed action)
Number of subjects: 192
Study: 36948568

Group type: EXPERIMENTAL
Intervention: Intravenous Ferric Carboxymaltose (10 mL, 50 mg Fe)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 36948572

Group type: EXPERIMENTAL
Intervention: Continuous rhythm monitoring with implantable loop recorder
Number of subjects: 392
Study: 36948576

Group type: EXPERIMENTAL
Intervention: Probiotic therapy to restore ethanolamine-metabolising capacity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Faecal conditioned media
Number of subjects: 0
Study: 36948733

Group type: EXPERIMENTAL
Intervention: Culprit lesion-only PCI
Number of subjects: 1015
Study: 36949116

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannulae (HFNC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Noninvasive positive pressure ventilation (NIPPV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: NIPPV
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HFNC
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HFNC and NIPPV
Number of subjects: 40
Study: 36949155

Group type: EXPERIMENTAL
Intervention: Asciminib monotherapy 10-200 mg once or twice daily
Number of subjects: 115
Study: 36949248

Group type: EXPERIMENTAL
Intervention: Ulotaront 150 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 36949284

Group type: EXPERIMENTAL
Intervention: High-implementer group (mean of 2.2 additional interventions)
Number of subjects: 10150

Group type: COMPARATOR
Intervention: Low-implementer group
Number of subjects: 10150
Study: 36949412

Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of quadriceps rectus femoris (QRF) on admission and discharge using a Chieson model ECO2 ultrasound system.
Number of subjects: 157
Study: 36949478

Group type: COMPARATOR
Intervention: Standard medical therapy (SMT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard medical therapy (SMT) + thoracic endovascular aortic repair (TEVAR)
Number of subjects: 0
Study: 36949485

Group type: EXPERIMENTAL
Intervention: Differentiated service delivery (DSD) models at clinic and community levels
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Community distribution points (CDPs) for diabetes or hypertension
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control arm with primary care clinics providing diabetes and hypertension care services without RHMs
Number of subjects: 84
Study: 36949505

Group type: EXPERIMENTAL
Intervention: Supervised six-week endurance exercise programme (2×90 min/week)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Health education and exercise programme
Number of subjects: 327
Study: 36949577

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 36949579

Group type: EXPERIMENTAL
Intervention: IDP-126 (clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15%)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 394

Group type: COMPARATOR
Intervention: Dyad combinations (three different gels)
Number of subjects: 394
Study: 36949623

Group type: EXPERIMENTAL
Intervention: 4 months of rifampin
Number of subjects: 6656

Group type: COMPARATOR
Intervention: 9 months of isoniazid
Number of subjects: 6656
Study: 36949846

Group type: EXPERIMENTAL
Intervention: Movement Group (twice-weekly group improvisational dance classes for 12 weeks)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Movement Alone (same dance movement and auditory stimuli without social interaction)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Social Group (improvisational party games without movement)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Usual Care control
Number of subjects: 111
Study: 36949896

Group type: EXPERIMENTAL
Intervention: 6-month short message service (SMS) intervention, messages sent two times per week, included SSB intake assessments, educational information, infographic URLs, and strategies.
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Caregivers with higher income and education levels.
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Caregivers with reduced intention to change SSB behaviors.
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Caregivers with higher baseline SSB intake.
Number of subjects: 357
Study: 36949953

Group type: EXPERIMENTAL
Intervention: Third dose of CoronaVac
Number of subjects: 94
Study: 36950217

Group type: EXPERIMENTAL
Intervention: Everolimus 4.5 mg/m² orally
Number of subjects: 11
Study: 36950303

Group type: EXPERIMENTAL
Intervention: Flexor tenotomy of claw/hammer toes
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard of care including orthosis and shoe offloading
Number of subjects: 66
Study: 36950415

Group type: EXPERIMENTAL
Intervention: Propofol at a dose of 1.5 mg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol at a dose of 1.5 mg/kg in Group N
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol at a dose of 1.5 mg/kg in Group OW
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol at a dose of 1.5 mg/kg in Group O
Number of subjects: 120
Study: 36950450

Group type: EXPERIMENTAL
Intervention: Lomecel-B (intramyocardial injections)
Number of subjects: 10
Study: 36950857

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (calcium and multivitamins) post-gastrectomy
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Postoperative adherence to calcium and multivitamin supplementation
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Pre- and postoperative nutritional counseling
Number of subjects: 94
Study: 36950929

Group type: EXPERIMENTAL
Intervention: Lasmiditan (initial dose 100 mg, adjustable to 50 mg or 200 mg)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 477
Study: 36951052

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 1070
Study: 36951156

Group type: EXPERIMENTAL
Intervention: Oral azacitidine maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36951168

Group type: EXPERIMENTAL
Intervention: Vismodegib with ribavirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vismodegib with ribavirin and decitabine
Number of subjects: 0
Study: 36951196

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted trivalent inactivated influenza vaccine (aTIV)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Nonadjuvanted vaccine (TIV)
Number of subjects: 85
Study: 36951387

Group type: EXPERIMENTAL
Intervention: Ixazomib
Number of subjects: 0
Study: 36951813

Group type: EXPERIMENTAL
Intervention: Leadless ventricular pacemaker
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36951827

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg once daily
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg 3 times weekly
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg once weekly
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ki-67
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Progesterone receptor
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Sex hormone-binding globulin and high-density lipoprotein cholesterol
Number of subjects: 180

Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 180
Study: 36951834

Group type: EXPERIMENTAL
Intervention: nal-IRI plus FU/LV
Number of subjects: 178

Group type: COMPARATOR
Intervention: FU/LV alone
Number of subjects: 178
Study: 36951854

Group type: EXPERIMENTAL
Intervention: Handheld, illuminated optical magnifiers
Number of subjects: 29
Study: 36951871

Group type: EXPERIMENTAL
Intervention: 1% tropicamide autorefraction
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: 1% cyclopentolate retinoscopy
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Mean spherical equivalent with 1% tropicamide
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Mean spherical equivalent with SureSight
Number of subjects: 473
Study: 36951890

Group type: EXPERIMENTAL
Intervention: Wearable sensor data during ILI events
Number of subjects: 2435

Group type: COMPARATOR
Intervention: Care-seeking participants
Number of subjects: 2435

Group type: COMPARATOR
Intervention: Participants with confirmed influenza infection
Number of subjects: 2435

Group type: EXPERIMENTAL
Intervention: Correlative analyses between wearable sensor data and patient-reported outcomes
Number of subjects: 2435
Study: 36951893

Group type: EXPERIMENTAL
Intervention: BSA weighted left ventricular end-diastolic diameter (bLVEDD)
Number of subjects: 9474

Group type: EXPERIMENTAL
Intervention: Left ventricular end-diastolic diameter (LVEDD)
Number of subjects: 9474

Group type: EXPERIMENTAL
Intervention: BSA
Number of subjects: 9474

Group type: EXPERIMENTAL
Intervention: LVEDD
Number of subjects: 9474

Group type: EXPERIMENTAL
Intervention: Categorical bLVEDD
Number of subjects: 9474
Study: 36951958

Group type: EXPERIMENTAL
Intervention: CMVpp65-sensitized T cells (CMVpp65-VSTs)
Number of subjects: 67
Study: 36951987

Group type: EXPERIMENTAL
Intervention: Vulvodynia group (n = 151)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (n = 106)
Number of subjects: 151
Study: 36952010

Group type: EXPERIMENTAL
Intervention: Cognitive games integrated in the dreaMS app, played twice a week for 5 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 31
Study: 36952231

Group type: EXPERIMENTAL
Intervention: Avelumab (10 mg/kg intravenously every 2 weeks) + Cabozantinib (20 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Avelumab (10 mg/kg intravenously every 2 weeks) + Cabozantinib (40 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Avelumab (10 mg/kg intravenously every 2 weeks) + Cabozantinib (60 mg/day)
Number of subjects: 12
Study: 36952372

Group type: EXPERIMENTAL
Intervention: Digital ostomy leakage notification system
Number of subjects: 25
Study: 36952468

Group type: EXPERIMENTAL
Intervention: FOCS intervention
Number of subjects: 91
Study: 36952472

Group type: EXPERIMENTAL
Intervention: CABM survivors with incident headache/worsening headache intensity at 12 months post-CABM
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: CABM survivors with unfavourable disability outcome (GOS)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: CABM survivors with incident headache/worsening headache since meningitis onset
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: CABM survivors with incident hearing impairment
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: CABM impairments
Number of subjects: 284
Study: 36952517

Group type: EXPERIMENTAL
Intervention: SMART (Self-Management for Amputee Rehabilitation using Technology) with weekly support sessions from a trained peer mentor for goal setting and action planning for six weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care with weekly social contacts for six weeks.
Number of subjects: 0
Study: 36952634

Group type: EXPERIMENTAL
Intervention: Niraparib + Abiraterone Acetate plus prednisone (niraparib + AAP)
Number of subjects: 670

Group type: COMPARATOR
Intervention: Placebo + Abiraterone Acetate (placebo + AAP)
Number of subjects: 670
Study: 36958330

Group type: EXPERIMENTAL
Intervention: High-fat/high-sugar snack
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-fat/low-sugar snack
Number of subjects: 0
Study: 36958364

Group type: EXPERIMENTAL
Intervention: Ravulizumab plus best supportive care (BSC)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Ravulizumab plus BSC
Number of subjects: 202